Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population

Table 1 Patients’ characteristics

Variable	Number of patients	Percentage (%)
Age (yr)
< 40	68	28.3
> 40	172	71.7
Sex
Female	110	45.8
Male	130	54.2
BMI (kg/m2)
< 28	131	54.5
> 28	109	45.5
Liver enzymes
Normal	115	47.9
Abnormal	125	52.1
PCR (IU/mL)
< 800 000	138	57.5
> 800 000	102	42.5
Duration
Completed	215	89.6
Incomplete	25	10.4
Side effects
Present	125	52.1
Absent	115	47.9
Drug
Peg IFN α-2A	138	57.5
Peg IFN α-2B	102	42.5
Genotype
Genotype 1	46	19.2
Genotype 2	9	3.8
Genotype 3	15	6.3
Genotype 4	82	34.2
Genotype 5	1	0.4
Not identified	5	2.1
No records	82	34.2
ETVR
Responded	160	66.7
No response	80	33.3
SVR
SVR	139	58.0
No SVR	101	42.0

BMI: Body mass index; ETVR: End of treatment virological response; SVR: Sustained virological response.

Table 2 Overall treatment outcomes

Treatment outcome	Frequency (%)
SVR	139 (58)
Relapse	17 (7)
Primary non responder	61 (25)
Intolerant	23 (10)
Total	240 (100)

Table 3 Characteristics of patients who achieved an SVR

Variable	Number of patients	SVR (%)	P value
Age (yr)
< 40	51	75	0.001
> 40	88	51
Sex
Female	57	52	NS
Male	82	63
BMI (kg/m2)
< 28	85	65	0.01
> 28	54	49
PCR (IU/mL)
< 800 000	88	64	0.023
> 800 000	51	50
Drug
Peg IFN α-2A 180 μg/wk	85	62	NS
Peg IFN α-2B 1.5 μg/kg per week	54	53
Liver enzymes
Normal	69	60	NS
Abnormal	70	56
Treatment duration
Completed	137	64	0.00001
Not completed	2	8

NS: No significant.